Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Konstantinos E. Tsaparikos
Observed names:
K. E. Tsaparikos,
Konstantinos Tsaparikos
Institution:
Pfizer (United States)
Observed institution:
Pfizer (United States)
OpenAlex ID:
A5000804175
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
2015
·
Helen Y. Zou
, Luc Friboulet
, et al.
·
Cancer Cell
·
503
PDF
Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice
1999
·
Vincent A. Pollack
, Douglas M. Savage
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
475
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
2014
·
Shihao Chen
, Li-Fen Lee
, et al.
·
Cancer Immunology Research
·
300
PDF
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
2014
·
Qinhua Huang
, Ted W. Johnson
, et al.
·
Journal of Medicinal Chemistry
·
129
PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy
2010
·
Jitesh P. Jani
, Joel Arcari
, et al.
·
Molecular Cancer Therapeutics
·
98
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
2023
·
Shikhar Sharma
, Chi-Yeh Chung
, et al.
·
Cell chemical biology
·
90
PDF
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2018
·
Bruno Gomes
, Gregory Driessens
, et al.
·
Molecular Cancer Therapeutics
·
90
PDF
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
2013
·
Douglas D. Fang
, Cathy C. Zhang
, et al.
·
PLoS ONE
·
44
PDF
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice
2017
·
Timothy S. Fisher
, Andrea T. Hooper
, et al.
·
Cancer Immunology Immunotherapy
·
43
Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors
2016
·
Joseph Tumang
, Bruno Gomes
, et al.
·
Cancer Research
·
29
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line
2013
·
Douglas D. Fang
, Joan Cao
, et al.
·
Frontiers of Medicine
·
23
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016
·
Casey Ager
, Matthew Reilley
, et al.
·
Journal for ImmunoTherapy of Cancer
·
18
PDF
Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.
2013
·
Helen Y. Zou
, Lars R. Engstrom
, et al.
·
Molecular Cancer Therapeutics
·
15
Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models
2011
·
Amy J. Jackson-Fisher
, Melissa J. McMahon
, et al.
·
Cancer Research
·
13
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621
2012
·
Neil R. Michaud
, Jitesh P. Jani
, et al.
·
mAbs
·
9
PDF
Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.
2013
·
Helen Y. Zou
, Lars R. Engstrom
, et al.
·
Molecular Cancer Therapeutics
·
8
Regulated Expression of the Human Mutant ras Gene After Transfection of BALB/c Mouse Embryo Fibroblast Cells
1988
·
K. R. Harewood
, D. S. Wilson
, et al.
·
JNCI Journal of the National Cancer Institute
·
5
Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models
2015
·
Ping Wei
, Ming Qiu
, et al.
·
Cancer Research
·
4
Effects of the Antibiotic Tunicamycin on Murine Lymphosarcoma Cells
1982
·
S. K. Joshi
, Konstantinos Tsaparikos
, et al.
·
Proceedings of the Indiana Academy of Science
·
3
Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
2015
·
Luc Friboulet
, Helen Zou
, et al.
·
Cancer Research
·
2
Abstract 4483: Establishing patient-derived colorectal cancer stem cell models with a PIK3CA mutation for the development of inhibitory drugs as targeted therapies
2010
·
Douglas D. Fang
, Yin Gu
, et al.
·
Cancer Research
·
1
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023
·
Bruno Gomes
, Gregory Driessens
, et al.
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023
·
Bruno Gomes
, Gregory Driessens
, et al.
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023
·
Bruno Gomes
, Gregory Driessens
, et al.
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023
·
Bruno Gomes
, Gregory Driessens
, et al.
Show more works
View as search
Works count:
39
Citation count:
1,902
H-index:
13
I10-index:
14
Year
Topic
Type